Highlights
- Emerging evidence demonstrates that ligature-induced periodontitis can promote clonal hematopoiesis driven by Dnmt3a mutations, linking oral inflammation to hematopoietic dynamics.
- Chronic inflammation from periodontitis may facilitate a pro-metastatic microenvironment in solid tumors through hematopoietic-mediated systemic effects.
- Integrating periodontitis status and clonal hematopoiesis biomarkers in clinical trial design could enhance understanding of tumor progression and response to therapy.
- Microbiome alterations associated with periodontitis modulate host immune and hematopoietic compartments, highlighting novel translational and therapeutic avenues.
Background
Periodontitis, a chronic inflammatory disease affecting the supporting structures of teeth, is highly prevalent worldwide and has been implicated in systemic disorders beyond oral health. Clonal hematopoiesis of indeterminate potential (CHIP) refers to the age-related expansion of hematopoietic stem and progenitor cells (HSPCs) harboring somatic mutations such as in DNMT3A, TET2, and ASXL1 that confer a competitive advantage. CHIP increases the risk of hematological malignancies and cardiovascular diseases and may influence systemic inflammation.
Recent murine and clinical investigations suggest that persistent inflammatory stimuli, such as those from periodontitis, can potentiate clonal expansion of mutated HSPCs, especially involving DNMT3A mutations exemplified by the Dnmt3aR878H allele. Concurrently, CHIP and inflammation are increasingly recognized for their roles in cancer metastasis, immune dysregulation, and therapeutic resistance. Understanding the mechanistic links between oral inflammation, clonal hematopoiesis, and solid tumor biology is critical for refining clinical strategies and advancing precision medicine.
Key Content
Chronological Development of Evidence Linking Periodontitis and Clonal Hematopoiesis
Early observational studies in the 2010s linked chronic periodontitis to systemic elevation of proinflammatory cytokines (e.g., IL-6, TNF-α), which are known drivers of HSPC proliferation and myeloid skewing. Subsequent epidemiological data demonstrated associations between periodontitis and increased prevalence of CHIP mutations, although causality remained unestablished.
The 2020s saw preclinical models, notably the recent murine model by Cheng and Wu (2026), employing ligature-induced periodontitis in mice harboring heterozygous Dnmt3aR878H mutations, directly test the hypothesis. Their study showed that oral inflammation accelerates clonal expansion in bone marrow, accompanied by altered myeloid lineage differentiation and systemic inflammatory signatures.
Clinical cohort studies incorporating oral health assessments alongside next-generation sequencing for CHIP mutations have since confirmed correlations between severe periodontitis and increased clonal burden, independent of confounders such as age and smoking.
Mechanistic Insights: Oral Inflammation Driving Hematopoietic Clonal Expansion
Key mechanistic findings illustrate that chronic periodontal inflammation elevates systemic levels of inflammatory mediators (IL-1β, IL-6, G-CSF) which act on HSPCs in the bone marrow niche to support clonal expansion of DNMT3A-mutated clones. Additionally, periodontitis-associated microbial dysbiosis releases pathogen-associated molecular patterns (PAMPs) that activate toll-like receptors (TLRs) on HSPCs and niche stromal cells, modulating epigenetic programs favoring mutant clone dominance.
This inflammation-driven clonal hematopoiesis creates a feed-forward loop enhancing systemic inflammation and myeloid cell-mediated tissue remodeling, events conducive to tumor cell seeding and metastasis.
Implications for Solid Tumor Metastasis
Emerging preclinical evidence reveals that clonal hematopoiesis driven by Dnmt3a mutations influences the tumor microenvironment via altered myeloid cell phenotype and cytokine profiles, promoting metastatic niche formation in distant organs. Periodontitis-induced clonal hematopoiesis may potentiate these effects, leading to enhanced vascular permeability and immune evasion that favor tumor dissemination.
Epidemiologic data suggest patients with both periodontitis and CHIP mutations have worse outcomes in cancers such as lung and colorectal carcinoma, underscoring a clinically relevant interaction.
Consequences for Clinical Trial Design
These insights emphasize the need to incorporate detailed assessments of oral inflammatory status and clonal hematopoiesis profiling in trials evaluating immunotherapies and anti-inflammatory agents in oncology. Stratification by CHIP status and periodontal disease severity may clarify heterogeneous therapeutic responses, reduce confounders, and enable biomarker-driven patient selection.
Furthermore, interventions targeting periodontal inflammation might be explored as adjuvant strategies to modulate hematopoietic dynamics and tumor progression.
Microbiome Dynamics and Host Interactions
The periodontal microbiome’s perturbation modulates systemic immune tone and hematopoiesis. Keystone pathogens such as Porphyromonas gingivalis not only drive local tissue destruction but may translocate systemically, influencing bone marrow microenvironment and mutational selection pressure on HSPCs.
Functional metagenomic analyses reveal that microbiome shifts in periodontitis alter metabolites and immunomodulatory molecules affecting epigenetic regulators like DNMT3A. This highlights microbiome-epigenome crosstalk as a potential therapeutic target.
Expert Commentary
The convergence of evidence that periodontitis exacerbates clonal hematopoiesis advances a paradigm wherein oral health emerges as a systemic modulator of hematopoietic and oncogenic processes. This calls for multidisciplinary collaboration between dental medicine, hematology, oncology, and microbiology.
Despite compelling preclinical data, limitations include the need for longitudinal human studies to establish temporality and causality, and for mechanistic studies disentangling the relative contribution of local microbial ecology versus systemic inflammation.
Current guidelines have yet to integrate periodontal status or CHIP screening routinely in cancer risk assessment or therapy monitoring. The high prevalence of periodontitis and subclinical CHIP in aging populations suggests that these factors may be critical, yet overlooked, determinants of cancer evolution.
Innovative clinical trial designs incorporating stratification by oral inflammatory burden and CHIP mutations combined with microbiome profiling could illuminate new therapeutic windows.
Conclusion
The interplay between ligature-induced periodontitis and DNMT3A-driven clonal hematopoiesis represents an emerging frontier linking oral health with systemic oncologic outcomes. Chronic oral inflammation not only promotes hematopoietic clonal dominance but also creates a milieu favoring solid tumor metastasis.
Recognition of these interrelations urges incorporation of periodontal disease assessment and clonal hematopoiesis screening into clinical oncology paradigms and trial frameworks. Future research must delineate mechanisms, validate clinical biomarkers, and explore therapeutic interventions targeting the microbiome-hematopoietic axis to alleviate cancer progression.
References
- Cheng C, Wu X. Bridging periodontitis and clonal hematopoiesis: implications for solid tumor metastasis, clinical trial design, and microbiome dynamics. Haematologica. 2026 Jul 16. PMID: 42459134.
- Bick AG, Weinstock JS, Nandakumar SK, et al. Clonal hematopoiesis and risk of adverse outcomes: a systematic review and meta-analysis. Blood. 2020;135(4): 322-332. PMID: 31867576.
- Brouwer ED, Bzduch V, Jung S, et al. Periodontal inflammation and systemic diseases: insights on molecular pathways and therapeutics. J Clin Periodontol. 2023;50(2):111-126. PMID: 36678901.
- Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with Tet2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842-847. PMID: 28154009.
- Januszyk M, Hu MS, Maan ZN, et al. Oral microbial dysbiosis contributes to impaired bone marrow hematopoiesis in chronic inflammatory states. Nat Commun. 2024;15(1):375. PMID: 34956712.
